Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest MorphoSys Stories

2012-04-19 02:29:45

MONROVIA, Calif., April 19, 2012 /PRNewswire/ -- Xencor, Inc. announced today that the Company received a milestone payment under an antibody optimization collaboration agreement with CSL Limited. The payment was triggered by filing of an investigational new drug application with the FDA for a novel monoclonal antibody that was optimized using Xencor's XmAb® antibody engineering technology. This is the first XmAb candidate to move into human clinical testing under the agreement with CSL...

2012-04-04 02:29:50

MONROVIA, Calif., April 4, 2012 /PRNewswire/ -- Xencor, Inc. announced today that the Company received a milestone payment under a technology license agreement with Boehringer Ingelheim. The payment was triggered by a regulatory submission to begin Phase 1 clinical trials of a novel monoclonal antibody that was optimized using Xencor's XmAb® antibody engineering technology. This is the second XmAb candidate entering human clinical trials under the agreement with Boehringer Ingelheim....

2012-01-06 07:00:00

MONROVIA, Calif., Jan. 6, 2012 /PRNewswire/ -- Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, announced today that the U.S. Patent and Trademark Office has issued Xencor a broad patent covering optimized monoclonal antibody variants and their application for extending in vivo half-life of antibodies. U.S. Patent 8,088,376 is the latest in Xencor's expanding portfolio of patents covering...

2011-12-12 07:30:00

GAITHERSBURG, Md., Dec. 12, 2011 /PRNewswire/ -- Zyngenia, Inc., a biopharmaceutical company developing the next generation of antibody-based drugs called Zybodies(TM), announced today that it has promoted David M. Hilbert, Ph.D., to Chief Scientific Officer and appointed Daniel L. Menichella as Chief Business Officer. "Since our start in September 2009, Zyngenia has made tremendous progress in both developing novel multi-specific biological drugs and in validating our technology...

2011-10-21 07:00:00

MONROVIA, Calif., Oct. 21, 2011 /PRNewswire/ -- Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, announced today the initiation of a Phase 1 clinical trial of XmAb®5871, the company's therapeutic antibody for the treatment of autoimmune diseases. XmAb5871 uses a novel dual-targeted approach to potently suppress autoimmune disorders that may avoid some of the side...

2011-07-01 08:00:00

GAITHERSBURG, Md., July 1, 2011 /PRNewswire/ -- Sigma-Tau Pharmaceuticals, Inc. announced the appointment of Dave Lemus as its new vice president of finance, effective July 1, 2011. Lemus will join the leadership team at Sigma-Tau Pharmaceuticals U.S. corporate headquarters in Gaithersburg, Md. For the past 13 years, Lemus served as chief financial officer of MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX), one of the Europe's leading biotechnology companies focused on fully...

2011-04-19 11:00:00

BERLIN and BURLINGAME, California, April 19, 2011 /PRNewswire/ -- Germany is setting the bar in biotechnology and investors from all over the world are taking notice. Venture capital investments doubled from 2009 to 2010 to over $420 million. Industry revenues continue to grow, according to a new industry survey available Thursday. The growing importance of medical biotechnology has already led to industry clusters that are drawing companies to Germany. Germany Trade & Invest will be...

2011-01-06 15:09:00

THOUSAND OAKS, Calif. and MONROVIA, Calif., Jan. 6, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb(®)5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases. Under the terms of the agreement, Amgen has the option to an exclusive worldwide license following the completion of a...

2010-01-04 03:10:00

FREISING-WEIHENSTEPHAN, Germany, January 4 /PRNewswire/ -- Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect. Mr. Yoder takes over the position from interim CEO and co-founder Claus Schalper, who will remain CFO. Mr. Yoder joins Pieris from MorphoSys AG, where he was General Counsel and Head of Licensing & IP, responsible for company-wide legal & IP, as well as several areas in business development. "We are delighted to have Steve on...

2008-11-13 03:00:05

MARTINSRIED, Germany, Nov. 13, 2008 (GLOBE NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) announced today the publication of preclinical data from its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF. The preclinical data, which will be presented today at the Human Antibodies and Hybridomas (HAH) Conference in New York, USA, provides strong supporting evidence for MOR103 as a treatment for rheumatoid...